Study # ARTEMIDE 03/D702FC00001

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1

Study Status:

Enrolling

Treatment Agent:

Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed

Description

The purpose of this study is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.This is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a 1L treatment for patients with non-squamous mNSCLC whose tumors express PD-L1 (TC ≥ 1%).

Resources and Links

National Clinical Trial Identified Number: NCT06627647

Information and next steps

Disease:

  • Non-Small Cell Lung Cancer

Study Phase:

III

Physician Name:

Department:

Ask a Question